ARTICLE | Clinical News
MGAWN1: Phase II started
July 20, 2009 7:00 AM UTC
MacroGenics began the double-blind, placebo-controlled, North American Phase II PARADIGM trial to evaluate a single dose of 30 mg/kg intravenous MGAWN1 in about 60 patients with suspected CNS infectio...